Boston Scientific Corp. (BSX)

$56.14

+0.25

(+0.45%)▲

Market is closed - opens 8 PM, 04 Dec 2023

Performance

  • $55.59
    $56.20
    $56.14
    downward going graph

    0.98%

    Downside

    Day's Volatility :1.09%

    Upside

    0.11%

    downward going graph
  • $43.84
    $56.14
    $56.14
    downward going graph

    21.91%

    Downside

    52 Weeks Volatility :21.91%

    Upside

    0.0%

    downward going graph

Returns

PeriodBoston Scientific Corp.
3 Months
5.33%
6 Months
8.34%
1 Year
20.47%
3 Years
64.39%

Highlights

Market Capitalization
81.5B
Book Value
$12.89
Dividend Share
0.0
Dividend Yield
1.94%
Earnings Per Share (EPS)
0.82
PE Ratio
67.84
PEG Ratio
2.53
Wall Street Target Price
60.48
Profit Margin
8.93%
Operating Margin TTM
17.27%
Return On Assets TTM
4.41%
Return On Equity TTM
6.68%
Revenue TTM
13.8B
Revenue Per Share TTM
9.52
Quarterly Revenue Growth YOY
11.3%
Gross Profit TTM
8.7B
EBITDA
3.5B
Diluted Eps TTM
0.82
Quarterly Earnings Growth YOY
1.83
EPS Estimate Current Year
2.01
EPS Estimate Next Year
2.24
EPS Estimate Current Quarter
0.48
EPS Estimate Next Quarter
0.52

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 36 Wall street analysts offering stock ratings for Boston Scientific Corp.(by analysts ranked 0 to 5 stars)
Based on 36 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
32
32
32
Hold
4
4
5
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 7.73%

Current $56.14
Target $60.48

Company Financials

FY17Y/Y Change
Revenue
9.0B
↑ 7.89%
Net Income
104.0M
↓ 70.03%
Net Profit Margin
1.15%
↓ 2.99%
FY18Y/Y Change
Revenue
9.8B
↑ 8.57%
Net Income
1.7B
↑ 1506.73%
Net Profit Margin
17.01%
↑ 15.86%
FY19Y/Y Change
Revenue
10.7B
↑ 9.28%
Net Income
4.7B
↑ 181.27%
Net Profit Margin
43.78%
↑ 26.77%
FY20Y/Y Change
Revenue
9.9B
↓ 7.66%
Net Income
-140.0M
↓ 102.98%
Net Profit Margin
-1.41%
↓ 45.19%
FY21Y/Y Change
Revenue
11.9B
↑ 19.92%
Net Income
1.0B
↓ 843.57%
Net Profit Margin
8.76%
↑ 10.17%
FY22Y/Y Change
Revenue
12.7B
↑ 6.68%
Net Income
698.0M
↓ 32.95%
Net Profit Margin
5.5%
↓ 3.26%
Q2 FY22Q/Q Change
Revenue
3.2B
↑ 7.2%
Net Income
260.0M
↑ 136.36%
Net Profit Margin
8.01%
↑ 4.37%
Q3 FY22Q/Q Change
Revenue
3.2B
↓ 2.28%
Net Income
188.0M
↓ 27.69%
Net Profit Margin
5.93%
↓ 2.08%
Q4 FY22Q/Q Change
Revenue
3.2B
↑ 2.27%
Net Income
140.0M
↓ 25.53%
Net Profit Margin
4.32%
↓ 1.61%
Q1 FY23Q/Q Change
Revenue
3.4B
↑ 4.53%
Net Income
314.0M
↑ 124.29%
Net Profit Margin
9.27%
↑ 4.95%
Q2 FY23Q/Q Change
Revenue
3.6B
↑ 6.2%
Net Income
270.0M
↓ 14.01%
Net Profit Margin
7.5%
↓ 1.77%
Q3 FY23Q/Q Change
Revenue
3.5B
↓ 2.0%
Net Income
504.0M
↑ 86.67%
Net Profit Margin
14.29%
↑ 6.79%
FY17Y/Y Change
Total Assets
19.0B
↑ 5.22%
Total Liabilities
12.0B
↑ 5.87%
FY18Y/Y Change
Total Assets
21.0B
↑ 10.28%
Total Liabilities
12.3B
↑ 2.02%
FY19Y/Y Change
Total Assets
30.6B
↑ 45.56%
Total Liabilities
16.7B
↑ 35.97%
FY20Y/Y Change
Total Assets
30.8B
↑ 0.7%
Total Liabilities
15.5B
↓ 7.41%
FY21Y/Y Change
Total Assets
32.2B
↑ 4.72%
Total Liabilities
15.6B
↑ 1.01%
FY22Y/Y Change
Total Assets
32.5B
↑ 0.74%
Total Liabilities
14.9B
↓ 4.56%
Q2 FY22Q/Q Change
Total Assets
32.2B
↓ 0.45%
Total Liabilities
14.9B
↓ 4.26%
Q3 FY22Q/Q Change
Total Assets
31.9B
↓ 0.75%
Total Liabilities
14.3B
↓ 4.22%
Q4 FY22Q/Q Change
Total Assets
32.5B
↑ 1.63%
Total Liabilities
14.9B
↑ 4.12%
Q1 FY23Q/Q Change
Total Assets
32.9B
↑ 1.3%
Total Liabilities
14.8B
↓ 0.76%
Q2 FY23Q/Q Change
Total Assets
33.6B
↑ 2.16%
Total Liabilities
15.1B
↑ 2.25%
Q3 FY23Q/Q Change
Total Assets
34.0B
↑ 1.32%
Total Liabilities
14.9B
↓ 1.34%
FY17Y/Y Change
Operating Cash Flow
1.4B
↑ 46.71%
Investing Cash Flow
-1.0B
↑ 13.87%
Financing Cash Flow
110.0M
↓ 153.4%
FY18Y/Y Change
Operating Cash Flow
310.0M
↓ 78.26%
Investing Cash Flow
-1.9B
↑ 90.2%
Financing Cash Flow
1.4B
↑ 1201.82%
FY19Y/Y Change
Operating Cash Flow
1.8B
↑ 492.26%
Investing Cash Flow
-5.0B
↑ 162.42%
Financing Cash Flow
3.0B
↑ 107.61%
FY20Y/Y Change
Operating Cash Flow
1.5B
↓ 17.86%
Investing Cash Flow
-411.0M
↓ 91.85%
Financing Cash Flow
293.0M
↓ 90.14%
FY21Y/Y Change
Operating Cash Flow
1.9B
↑ 24.01%
Investing Cash Flow
-1.6B
↑ 288.56%
Financing Cash Flow
-95.0M
↓ 132.42%
FY22Y/Y Change
Operating Cash Flow
1.5B
↓ 18.4%
Investing Cash Flow
-2.0B
↑ 25.92%
Financing Cash Flow
-548.0M
↑ 476.84%
Q2 FY22Q/Q Change
Operating Cash Flow
307.0M
↓ 629.31%
Investing Cash Flow
-29.0M
↓ 98.16%
Financing Cash Flow
-344.0M
↑ 5633.33%
Q3 FY22Q/Q Change
Operating Cash Flow
470.0M
↑ 53.09%
Investing Cash Flow
-225.0M
↑ 675.86%
Financing Cash Flow
-199.0M
↓ 42.15%
Q4 FY22Q/Q Change
Operating Cash Flow
807.0M
↑ 71.7%
Investing Cash Flow
-2.0B
↑ 793.78%
Financing Cash Flow
1000.0K
↓ 100.5%
Q1 FY23Q/Q Change
Operating Cash Flow
190.0M
↓ 76.46%
Investing Cash Flow
-484.0M
↓ 75.93%
Financing Cash Flow
-69.0M
↓ 7000.0%
Q2 FY23Q/Q Change
Operating Cash Flow
658.0M
↑ 246.32%
Investing Cash Flow
-840.0M
↑ 73.55%
Financing Cash Flow
43.0M
↓ 162.32%
Q3 FY23Q/Q Change
Operating Cash Flow
698.0M
↑ 6.08%
Investing Cash Flow
-1.5B
↑ 81.07%
Financing Cash Flow
16.0M
↓ 62.79%

Technicals Summary

Sell

Neutral

Buy

Boston Scientific Corp. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Boston Scientific Corp.
Boston Scientific Corp.
6.89%
8.34%
20.47%
64.39%
45.78%
Stryker Corporation
Stryker Corporation
7.03%
7.0%
22.49%
27.12%
71.25%
Dexcom, Inc.
Dexcom, Inc.
24.5%
-4.85%
-1.26%
40.0%
241.52%
Abbott Laboratories
Abbott Laboratories
9.3%
0.65%
-2.97%
-3.02%
41.21%
Medtronic Plc
Medtronic Plc
10.96%
-4.5%
0.46%
-29.59%
-19.0%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Boston Scientific Corp.
Boston Scientific Corp.
67.84
67.84
2.53
2.01
0.07
0.04
0.02
12.89
Stryker Corporation
Stryker Corporation
43.5
43.5
2.85
10.41
0.15
0.07
0.01
47.13
Dexcom, Inc.
Dexcom, Inc.
124.12
124.12
11.34
1.42
0.18
0.06
0.0
5.87
Abbott Laboratories
Abbott Laboratories
34.99
34.99
18.76
4.44
0.14
0.06
0.02
21.59
Medtronic Plc
Medtronic Plc
25.64
25.64
3.04
5.28
0.08
0.04
0.03
38.69
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$81.5B
45.78%
67.84
8.93%
Stryker Corporation
Stryker Corporation
Buy
$111.6B
71.25%
43.5
13.0%
Dexcom, Inc.
Dexcom, Inc.
Buy
$43.1B
241.52%
124.12
11.08%
Abbott Laboratories
Abbott Laboratories
Buy
$178.6B
41.21%
34.99
12.92%
Medtronic Plc
Medtronic Plc
Buy
$105.1B
-19.0%
25.64
12.84%

Institutional Holdings

  • BlackRock Inc

    9.39%

  • Vanguard Group Inc

    8.45%

  • FMR Inc

    8.05%

  • Massachusetts Financial Services Company

    4.27%

  • State Street Corporation

    4.23%

  • Wellington Management Company LLP

    2.87%

Company Information

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments.

Organization
Boston Scientific Corp.
Employees
45000
CEO
Mr. Michael F. Mahoney
Industry
Health Technology

Discover More

FAQs